Regional

Incyte to Present New Data on Dermatology Portfolio at EADV 2025 Congress

- by Timothy Alexander
Incyte

WILMINGTON, DE — Incyte (Nasdaq: INCY) will highlight new data from its dermatology portfolio at the European Association of Dermatology and Venerology (EADV) 2025 Congress in Paris, running September 17–20. Presentations will include late-breaking, oral, and poster sessions featuring clinical results for povorcitinib (INCB054707), an oral JAK1 inhibitor, and ruxolitinib cream (Opzelura®), a topical JAK1/2 inhibitor.

“Our presence at EADV demonstrates the significant progress across our dermatology portfolio,” said Pablo J. Cagnoni, M.D., President and Head of Research and Development at Incyte. “The late-breaking data from the STOP-HS clinical trial program reinforce the potential of povorcitinib to benefit patients impacted by hidradenitis suppurativa, a challenging and debilitating immune-mediated dermatologic condition. Data on ruxolitinib cream in new patient populations continues to demonstrate safety and efficacy in individuals with atopic dermatitis, vitiligo and prurigo nodularis.”

READ:  Second Front Systems Expands Game Warden Platform to AWS European Sovereign Cloud

Key abstracts include:

  • Hidradenitis Suppurativa: Phase 3 interim results from the STOP-HS program evaluating povorcitinib in moderate to severe cases (Sept. 17).
  • Prurigo Nodularis: Pooled efficacy and safety data for ruxolitinib cream from the Phase 3 TRuE-PN1 and TRuE-PN2 studies (Sept. 17).
  • Vitiligo: Findings on vitiligo-associated hearing loss in patients from a Phase 2 povorcitinib trial (Sept. 18).
  • Atopic Dermatitis: Poster data showing long-term disease control with ruxolitinib cream in pediatric patients.
  • Vitiligo: Additional posters covering lesion distribution, genital vitiligo, and combined therapy with NB-UVB phototherapy.
  • Multiple Indications: Long-term safety analyses of ruxolitinib cream across seven Phase 3 trials in atopic dermatitis and nonsegmental vitiligo.
READ:  Dräger to Showcase Next-Generation Surgical Light at Vizient Innovation Exchange

Incyte’s expanded slate of presentations reflects its strategic focus on immune-mediated dermatologic conditions and its push to bring new treatment options to patients across multiple indications.

For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.